Baseline characteristics
| Variable . | Bortezomib (n = 187) . | Control (n = 183) . |
|---|---|---|
| Age, years* | 59.1 (9.90) | 58.7 (8.80) |
| Male† | 59 (111) | 60 (109) |
| Double ASCT† | 5 (9) | 3 (6) |
| Myeloma subtype† | n = 187 | n = 183 |
| IgG | 55 (103) | 63 (116) |
| IgA | 26 (50) | 21 (39) |
| Light chain | 18 (33) | 14 (25) |
| Other | 1 (1) | 2 (3) |
| ISS disease stage† | n = 125 | n = 141 |
| I | 38 (48) | 41 (58) |
| II | 38 (48) | 31 (44) |
| III | 23 (29) | 28 (39) |
| β2-microglubilin (mg/L)‡ | 3.0/4.9 | 3.4/5.1 |
| Albumin (g/L)‡ | 36.8/35.8 | 37.0/36.2 |
| Creatinine (μmol/L)‡ | 82.0/118.1 | 83.0/123.1 |
| Hemoglobin (g/L)‡ | 112.0/114.1 | 110.0/111.7 |
| Platelets (×109/L)‡ | 249.0/252.9 | 243.0/253.9 |
| Fluorescence in situ hybridization analysis for cytogenetic abnormalities† | n = 73 | n = 66 |
| Absence of del(13q), t(4;14), or del(17p) | 75.3 (55) | 63.7 (42) |
| Presence of del(13q)§ | 21.9 (16) | 16.7 (11) |
| Presence of t(4;14) and/or del(17p) | 19.2 (14) | 19.7 (13) |
| Variable . | Bortezomib (n = 187) . | Control (n = 183) . |
|---|---|---|
| Age, years* | 59.1 (9.90) | 58.7 (8.80) |
| Male† | 59 (111) | 60 (109) |
| Double ASCT† | 5 (9) | 3 (6) |
| Myeloma subtype† | n = 187 | n = 183 |
| IgG | 55 (103) | 63 (116) |
| IgA | 26 (50) | 21 (39) |
| Light chain | 18 (33) | 14 (25) |
| Other | 1 (1) | 2 (3) |
| ISS disease stage† | n = 125 | n = 141 |
| I | 38 (48) | 41 (58) |
| II | 38 (48) | 31 (44) |
| III | 23 (29) | 28 (39) |
| β2-microglubilin (mg/L)‡ | 3.0/4.9 | 3.4/5.1 |
| Albumin (g/L)‡ | 36.8/35.8 | 37.0/36.2 |
| Creatinine (μmol/L)‡ | 82.0/118.1 | 83.0/123.1 |
| Hemoglobin (g/L)‡ | 112.0/114.1 | 110.0/111.7 |
| Platelets (×109/L)‡ | 249.0/252.9 | 243.0/253.9 |
| Fluorescence in situ hybridization analysis for cytogenetic abnormalities† | n = 73 | n = 66 |
| Absence of del(13q), t(4;14), or del(17p) | 75.3 (55) | 63.7 (42) |
| Presence of del(13q)§ | 21.9 (16) | 16.7 (11) |
| Presence of t(4;14) and/or del(17p) | 19.2 (14) | 19.7 (13) |